Alpha Cognition receives notice of allowance for US patent of novel AD drug
Click Here to Manage Email Alerts
A Vancouver-based biopharmaceutical company has secured a notice of allowance, presaging a U.S. patent for a crystalline formulation of a novel acetylcholinesterase inhibitor to treat Alzheimer’s disease.
In a press release, Alpha Cognition said it received the notice of allowance — which clears the way for eventual issuance of the patent —for its application entitled “Solid Forms of ALPHA-1062 Gluconate for Zunveyl.”
The mechanism of action for Zunveyl (benzgalantamine) binds neuronal nicotinic receptors, including the alpha-7 subtype, which, according to prior research, promotes cognition.
The patent, which is expected to last until 2042, will allow Alpha protection to develop a second commercially viable form of the drug should it choose to do so.
“Allowance of this composition-of-matter patent, covering a specific solid form of benzgalantamine, provides another important layer of proprietary intellectual property protection for our lead asset, Zunveyl, an FDA-approved medication for the treatment of mild to moderate Alzheimer’s disease,” Alpha Cognition CEO Michael McFadden said in the release.